Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

JR-441

PreclinicalSmall molecule

JJCR Pharmaceuticals Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mucopolysaccharidosis III-aActive, not recruiting

Mucopolysaccharidosis III-aPreclinical

Active, not recruiting

Timeline

Expected Milestones

Q4 2029

PreclinicalActive, not recruiting

Mucopolysaccharidosis III-a

NCT06095388

Clinical

Trials by Indication[1]

Mucopolysaccharidosis III-A1 trial

Phase I/II Study of Weekly Infusions of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Active, not recruiting·JJCR Pharmaceuticals Co., Ltd.·Preclinical·NCT06095388·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JR-441. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JR-441 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JR-441. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — JCR Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJCR Pharmaceuticals Co., Ltd.

Related News